Related references
Note: Only part of the references are listed.Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells
J. Etchin et al.
LEUKEMIA (2013)
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia
Sergej Konoplev et al.
LEUKEMIA & LYMPHOMA (2013)
Nuclear export of proteins and drug resistance in cancer
Joel G. Turner et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Survivin is highly expressed in CD34+38- leukemic stem/progenitor cells and predicts poor clinical outcomes in AML
Bing Z. Carter et al.
BLOOD (2012)
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
Rosa Lapalombella et al.
BLOOD (2012)
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
Parvathi Ranganathan et al.
BLOOD (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia
N. Anensen et al.
ONCOGENE (2012)
Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia
Steven M. Kornblau et al.
BLOOD (2011)
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia
Jianting Long et al.
BLOOD (2010)
Analysis of the p53 and MDM-2 gene in acute myeloid leukemia
Barbara Seliger et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal
Zhen Zhao et al.
GENES & DEVELOPMENT (2010)
The Isoforms of the p53 Protein
Marie P. Khoury et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Functional proteomic profiling of AML predicts response and survival
Steven M. Kornblau et al.
BLOOD (2009)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation
Pauline J. Van der Watt et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSIS
Aiguo Shen et al.
NEUROSURGERY (2009)
Awakening guardian angels: drugging the p53 pathway
Christopher J. Brown et al.
NATURE REVIEWS CANCER (2009)
Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer
Aurelia Noske et al.
CANCER (2008)
MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
L. Gu et al.
LEUKEMIA (2008)
Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice
Danielle C. Shing et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype:: Lessons from recent developments in the IARC TP53 database
Audrey Petitjean et al.
HUMAN MUTATION (2007)
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
Kensuke Kojima et al.
BLOOD (2006)
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
Paola Secchiero et al.
BLOOD (2006)
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells
Llorenc Coll-Mulet et al.
BLOOD (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Characterization of centrosomal association of nucleophosmin/B23 linked to Crm1 activity
K Shinmura et al.
FEBS LETTERS (2005)
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
K Kojima et al.
BLOOD (2005)
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis
M Yanada et al.
LEUKEMIA (2005)
Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation
S Kurki et al.
CANCER CELL (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Apoptosis genes and resistance to cancer therapy - What do the experimental and clinical data tell us?
M Brown et al.
CANCER BIOLOGY & THERAPY (2003)
The importance of p53 location: nuclear or cytoplasmic zip code?
A O'Brate et al.
DRUG RESISTANCE UPDATES (2003)
Nucleophosmin regulates the stability and transcriptional activity of p53
E Colombo et al.
NATURE CELL BIOLOGY (2002)
MDM2-dependent ubiquitination of nuclear and cytoplasmic P53
ZK Yu et al.
ONCOGENE (2000)
Share Paper
